Founded: March 1997

CEO and Scientific Director: Gualberto Ruano

Founders: Ruano and Kevin Rakin, executive vice president

Company Specialty: Development of "personalized medicines" by discovering gene variants and using them to develop clinically predictive gene profiles for existing drugs and to harness novel therapeutic targets for drugdiscovery

Disease Targets: Breast cancer and endothelial cardiovascular disease

Initial Capitalization: Approximately $10 million

Total Employees: 20